BRPI0817579A2 - Derivados de tiazol - Google Patents

Derivados de tiazol

Info

Publication number
BRPI0817579A2
BRPI0817579A2 BRPI0817579A BRPI0817579A2 BR PI0817579 A2 BRPI0817579 A2 BR PI0817579A2 BR PI0817579 A BRPI0817579 A BR PI0817579A BR PI0817579 A2 BRPI0817579 A2 BR PI0817579A2
Authority
BR
Brazil
Prior art keywords
thiazol derivatives
thiazol
derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Kai Schiemann
Melanie Schultz
Andree Blaukat
Ingo Kober
Wolfgang Staehle
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of BRPI0817579A2 publication Critical patent/BRPI0817579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
BRPI0817579 2007-10-05 2008-09-19 Derivados de tiazol BRPI0817579A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007047735A DE102007047735A1 (de) 2007-10-05 2007-10-05 Thiazolderivate
PCT/EP2008/007894 WO2009046842A2 (de) 2007-10-05 2008-09-19 Thialzolderivate zur behandlung von krebs

Publications (1)

Publication Number Publication Date
BRPI0817579A2 true BRPI0817579A2 (pt) 2015-04-07

Family

ID=40418145

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817579 BRPI0817579A2 (pt) 2007-10-05 2008-09-19 Derivados de tiazol

Country Status (16)

Country Link
US (1) US8557824B2 (pt)
EP (1) EP2209777B1 (pt)
JP (2) JP2010540580A (pt)
KR (1) KR20100080836A (pt)
CN (1) CN101815714A (pt)
AR (1) AR068658A1 (pt)
AU (1) AU2008310068B2 (pt)
BR (1) BRPI0817579A2 (pt)
CA (1) CA2701525C (pt)
DE (1) DE102007047735A1 (pt)
EA (1) EA201000550A1 (pt)
ES (1) ES2548525T3 (pt)
IL (1) IL204563A (pt)
MX (1) MX2010003365A (pt)
WO (1) WO2009046842A2 (pt)
ZA (1) ZA201003123B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5337711B2 (ja) * 2007-01-25 2013-11-06 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性アミド
DE102009049211A1 (de) * 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2012127885A1 (ja) 2011-03-18 2012-09-27 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
CN105793253B (zh) 2013-11-22 2019-08-23 法玛克亚公司 自分泌运动因子抑制剂化合物
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
TW202110831A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
GB0230162D0 (en) 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP1735622A2 (en) * 2004-04-13 2006-12-27 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) * 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
ATE430744T1 (de) 2005-08-18 2009-05-15 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EP1990332A1 (en) 2006-02-28 2008-11-12 Idemitsu Kosan Co., Ltd. Naphthacene derivative and organic electroluminescent device using same
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
EP1834954A1 (en) * 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
WO2007104557A2 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Also Published As

Publication number Publication date
AU2008310068B2 (en) 2014-05-01
IL204563A (en) 2017-03-30
EA201000550A1 (ru) 2010-10-29
AR068658A1 (es) 2009-11-25
IL204563A0 (en) 2010-11-30
WO2009046842A3 (de) 2009-06-25
KR20100080836A (ko) 2010-07-12
CA2701525A1 (en) 2009-04-16
US20100240676A1 (en) 2010-09-23
ZA201003123B (en) 2011-04-28
JP5843930B2 (ja) 2016-01-13
WO2009046842A2 (de) 2009-04-16
MX2010003365A (es) 2010-04-30
AU2008310068A1 (en) 2009-04-16
DE102007047735A1 (de) 2009-04-09
EP2209777A2 (de) 2010-07-28
US8557824B2 (en) 2013-10-15
CN101815714A (zh) 2010-08-25
CA2701525C (en) 2016-06-28
EP2209777B1 (de) 2015-07-29
ES2548525T3 (es) 2015-10-19
JP2014240392A (ja) 2014-12-25
JP2010540580A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2134708T3 (da) 3-Cyano-4-(4-tetrahydropyranphenyl)-pyridin-2-on-derivater
BRPI0817579A2 (pt) Derivados de tiazol
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0818457A2 (pt) Derivados de oxadiazol
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0816461A2 (pt) Derivados fungicidas de 2-alquiltio-2-quinolonolóxi-acetamida
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
DK2152370T3 (da) Aryletherpyridazinonderivater
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.